Tango Therapeutics, Inc. TNGX
25.00 USD -0.50 (-1.97%)
As ofNov 16, 2026, 12:42 PM EST
24.66 Day range 25.87
7.69 52-week range 34.39
- YTD
- +182.13%
- 1 year
- +205.96%
News
defenseworld.net Tango Therapeutics (NASDAQ:TNGX) Stock Price Breaks Above 50-Day Moving Average After Earnings Miss Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Tuesday after the company announced better than expected quarterly…benzinga.com JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47 JP Morgan analyst Brian Cheng maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and raises the price target from $46 to $47.
benzinga.com Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $45 to $40.
benzinga.com HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67 HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $68 to $67.
benzinga.com Tango Therapeutics Q3 EPS $(0.39) Misses $(0.35) Estimate Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.35) by 11.43 percent. This is a 378.57 percent decrease over…
globenewswire.com Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free…benzinga.com HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.
benzinga.com Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings U.S. stocks fell Friday: Dow -1.12%, S&P 500 -0.43%, Nasdaq -0.13%. Energy and oil rose; SLB gained 7% on strong results.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…benzinga.com Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today…
benzinga.com Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday U.S. stocks were mixed as the Dow gained 400 points. Winnebago jumped 7% on an EPS beat, while Super Micro and SpaceX rallied on strong outlooks.benzinga.com William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.
benzinga.com Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026 Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the…
